Director Arthur H. Amron filed a Form 4 with the SEC on November 18, 2026, disclosing two open-market purchases of Nephros Inc. common stock on November 16 and November 17, 2026.
Key Highlights
- First purchase: 5,000 shares of common stock acquired on November 16, 2026, at a weighted average price of $2.995, with individual transaction prices of $2.99 and $3.00.
- Second purchase: 2,500 shares acquired on November 17, 2026, at $2.84 per share.
- Post-transaction ownership: Following both purchases, Amron directly held 169,637 shares, according to the filing.
- Indirect holdings: An additional 25,546 shares are held indirectly by Amron Holdings LLC, over which Amron has voting and dispositive power as its controlling person.
- Derivative securities: Amron also holds two stock options to buy common stock: 7,323 shares at $2.13 (fully vested, expiring 05/14/2034) and 7,050 shares at $1.47 (vesting in tranches, expiring 01/01/2035).
Amron's Two-Day Open-Market Purchases of Nephros Common Stock
According to the filing, Arthur H. Amron, a director of Nephros Inc. (NASDAQ:NEPH), purchased a combined 7,500 shares of the company's common stock across two trading sessions. The first transaction, on November 16, 2026, involved 5,000 shares at a weighted average price of $2.995. The filing notes that these shares were purchased in two separate transactions at prices of $2.99 and $3.00, and that Amron "undertakes to provide to Nephros, Inc., any security holder of Nephros, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."
The second transaction, on November 17, 2026, involved 2,500 shares at a price of $2.84 per share. Both transactions are coded "P" (open-market purchase) in the filing. Following these two purchases, Amron's direct beneficial ownership stood at 169,637 shares of common stock. In addition, 25,546 shares are held indirectly through Amron Holdings LLC, an entity the filing states is controlled by Amron.
The filing also discloses two stock option positions held directly by Amron. The first covers 7,323 shares of common stock at an exercise price of $2.13, described as fully vested, with an expiration date of May 14, 2034. The second covers 7,050 shares at an exercise price of $1.47, expiring January 1, 2035, and vesting as to 2,350 shares on each of January 1, 2025, January 1, 2026, and January 1, 2027. No derivative securities were acquired or disposed of in the reported transactions.
What Was Disclosed
Director Arthur H. Amron reported the purchase of 7,500 shares of Nephros Inc. common stock on November 16 and 17, 2026, bringing his direct holdings to 169,637 shares, plus 25,546 shares held indirectly through Amron Holdings LLC.




Please wait processing your request...